Pediatric Myelodysplastic Syndromes

Clin Lab Med. 2021 Sep;41(3):517-528. doi: 10.1016/j.cll.2021.03.015. Epub 2021 Jun 24.

Abstract

Pediatric myelodysplastic syndromes (MDS) comprise less than 5% of childhood malignancies. Approximately 30% to 45% of pediatric MDS cases are associated with an underlying genetic predisposition syndrome. A subset of patients present with MDS/acute myeloid leukemia (AML) following intensive chemotherapy for an unrelated malignancy. A definitive diagnosis of MDS can often only be rendered pending a comprehensive clinical and laboratory-based evaluation, which frequently includes ancillary testing in a reference laboratory. Clinical subtypes, the current diagnostic schema, and the results of more recently performed next-generation sequencing studies in pediatric MDS are discussed here.

Keywords: Dysplasia; Inherited bone marrow failure; MDS; Myelodysplastic syndrome; Stem cell transplant.

Publication types

  • Review

MeSH terms

  • Child
  • Genetic Predisposition to Disease
  • Humans
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / genetics